Payment overview · 2025
General Payments
$606.26
8 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Vissing, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TOWSON, MD · NPI 1457352395
Verified facts
What the public records show
CMS Open Payments records show Robert Vissing, MD received $606.26 in general payments during 2025 across 8 reported records.
Corcept Therapeutics accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $124.98 | 20.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $120.59 | 19.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $113.54 | 18.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $101.40 | 16.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.66 | 15.9% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $20.70 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.48 | 2.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.91 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $606.26 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $120.59 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $113.54 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $101.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $96.66 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 742 | 231 |
| Amlodipine Besylate | Amlodipine Besylate | 468 | 141 |
| Losartan Potassium | Losartan Potassium | 362 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 351 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 104 |
| Gabapentin | Gabapentin | 305 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 89 |
| Lisinopril | Lisinopril | 295 | 91 |
| Metformin Hcl | Metformin Hcl | 238 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 209 | 60 |
| Alprazolam | Alprazolam | 199 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 63 |
| Simvastatin | Simvastatin | 192 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 58 |
| Eliquis | Apixaban | 174 | 41 |
| Omeprazole | Omeprazole | 170 | 51 |
| Montelukast Sodium | Montelukast Sodium | 158 | 49 |
| Furosemide | Furosemide | 145 | 52 |
| Tramadol Hcl | Tramadol Hcl | 145 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 37 |
| Xarelto | Rivaroxaban | 119 | 24 |
| Allopurinol | Allopurinol | 110 | 35 |
| Famotidine | Famotidine | 110 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 31 |
| Trazodone Hcl | Trazodone Hcl | 98 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 19 |
| Meloxicam | Meloxicam | 93 | 32 |
| Carvedilol | Carvedilol | 92 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 29 |
| Potassium Chloride | Potassium Chloride | 90 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 30 |
| Pregabalin | Pregabalin | 83 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 25 |
| Lorazepam | Lorazepam | 75 | 12 |
| Sertraline Hcl | Sertraline Hcl | 73 | 20 |
| Glimepiride | Glimepiride | 72 | 19 |
| Prednisone | Prednisone | 71 | 44 |
| Nifedipine Er | Nifedipine | 68 | 24 |
| Metformin Hcl Er | Metformin Hcl | 67 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 20 |
| Atenolol | Atenolol | 64 | 18 |
| Methylprednisolone | Methylprednisolone | 64 | 52 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 11 |
| Clonazepam | Clonazepam | 58 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 58 | 51 |
| Synthroid | Levothyroxine Sodium | 57 | 16 |
| Memantine Hcl | Memantine Hcl | 56 | 15 |
| Celecoxib | Celecoxib | 55 | 11 |
| Ketoconazole | Ketoconazole | 55 | 30 |
| Valsartan | Valsartan | 55 | 20 |
| Jardiance | Empagliflozin | 54 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 15 |
| Diazepam | Diazepam | 50 | 13 |
| Spironolactone | Spironolactone | 50 | 19 |
| Bupropion Xl | Bupropion Hcl | 49 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 16 |
| Irbesartan | Irbesartan | 45 | 13 |
| Mirtazapine | Mirtazapine | 43 | 15 |
| Temazepam | Temazepam | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 11 |
| Ozempic | Semaglutide | 41 | suppressed |
| Linzess | Linaclotide | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 12 |
| Glipizide Er | Glipizide | 35 | 11 |
| Ezetimibe | Ezetimibe | 34 | 14 |
| Ibuprofen | Ibuprofen | 34 | 14 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Topiramate | Topiramate | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $606.26 · 8 records | Corcept Therapeutics | BREZTRI, INSPIRE, Kerendia, Korlym, Ozempic, Rybelsus, SYNTHROID, TMS NeuroHealth Centers Inc., UBRELVY, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error